Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...
Publications
2 shownFrequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 4,081
- Institution
- Prisma Health
External Links
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.